证券代码：000423 证券简称：东阿阿胶 公告编号：2024-24 东阿阿胶股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 拟续聘毕马威华振会计师事务所（特殊普通合伙）（以下简称"毕马威华振"） 事项，符合财政部、国务院国资委、证监会印发的《国有企业、上市公司选聘会 计师事务所管理办法》（财会〔2023〕4 号）等相关规定。 东阿阿胶股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开第十 届董事会第二十五次会议，审议通过了《关于续聘会计师事务所的议案》。现将 具体情况公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1．基本信息 毕马威华振会计师事务所于 1992 年 8 月 18 日在北京成立，于 2012 年 7 月 5 日获财政部批准转制为特殊普通合伙的合伙制企业，更名为毕马威华振会计师事 务所（特殊普通合伙），2012 年 7 月 10 日取得工商营业执照，并于 2012 年 8 月 1 日正式运营。毕马威华振总所位于北京，注册地址为北京市东城区东长安街 1 号东方 ...

一、董事会会议召开情况 1.东阿阿胶股份有限公司（以下简称"公司"）第十届董事会第二十五次 会议，于 2024 年 4 月 21 日以邮件方式发出会议通知。 2.本次董事会会议，于 2024 年 4 月 24 日以通讯表决方式召开。 3.会议应出席会议董事 9 人，实际出席会议董事 9 人。 4.本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 证券代码：000423 证券简称：东阿阿胶 公告编号：2024-20 东阿阿胶股份有限公司 第十届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 经与会董事认真讨论，本次会议审议并通过了以下议案： 1.《关于 2024 年第一季度报告的议案》 本议案提交董事会前，已经公司第十届董事会审计委员会审议通过。 经审议，董事会认为公司《2024 年第一季度报告》的编制，符合法律、法规、 中国证监会和深圳证券交易所的相关规定。报告内容真实、准确、完整地反映了 公司实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 本事项具体内容，详 ...

东阿阿胶股份有限公司 独立董事工作制度 （2024 年 4 月 24 日 经公司第十届董事会第二十五次审议通过， 尚需提交股东大会审议） 第一章 总则 第一条 为进一步完善东阿阿胶股份有限公司（以下简称"公司"） 法人治理结构，充分发挥独立董事在公司治理中的作用，促进公司规 范运作，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司治理准则》《上市公司独立董事管理办法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》和《东阿阿胶股份有限公司章程》（以 下简称"《公司章程》"）等有关规定，特制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者 其他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制 人等单位或个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当 按照法律、行政法规、中国证券监督管理委员会（以下简称"中国证 监会"）规定、深圳证券交易所业务规则和《公司章程》的规定，认 真履行职责，在董 ...

Financial Performance - The company's revenue for Q1 2024 reached ¥1,453,383,433.75, representing a 35.95% increase compared to ¥1,069,042,839.05 in the same period last year[7] - Net profit attributable to shareholders was ¥353,403,544.67, up 53.43% from ¥230,335,474.70 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥328,636,170.06, reflecting a 54.79% increase from ¥212,304,365.91 in the previous year[7] - Basic earnings per share increased to ¥0.5488, a rise of 53.42% compared to ¥0.3577 in the same period last year[7] - Operating profit for the quarter was ¥409,884,421.49, marking a 46.92% increase from ¥278,978,406.83 in the same period last year[11] - The total profit for the quarter was ¥412,163,508.55, up 47.84% from ¥278,794,220.63 year-on-year[11] - Total operating revenue for Q1 2024 reached ¥1,453,383,433.75, a 36% increase compared to ¥1,069,042,839.05 in the same period last year[23] - Net profit attributable to shareholders was ¥353,403,544.67, representing a 53% increase from ¥230,335,474.70 in Q1 2023[24] - Earnings per share (EPS) for Q1 2024 was ¥0.5488, compared to ¥0.3577 in the previous year, marking a 53% increase[25] - The company reported a total comprehensive income of ¥353,295,916.15, compared to ¥230,505,318.53 in Q1 2023, reflecting strong overall performance[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥13,400,243,434.38, a slight increase of 0.71% from ¥13,306,306,533.41 at the end of the previous year[7] - The total current liabilities decreased to CNY 2.22 billion from CNY 2.41 billion, a reduction of about 7.67%[20] - Total liabilities amounted to ¥2,382,258,047.25, a decrease from ¥2,565,744,617.42 in the previous year[21] - Total equity attributable to shareholders increased to ¥10,996,278,203.45 from ¥10,719,014,633.60 year-over-year[21] Cash Flow - The company reported a decrease in cash flow from operating activities, which was ¥638,470,330.70, down 5.89% from ¥678,397,600.33 in the previous year[7] - Cash outflow from operating activities totaled ¥1,031,308,257.64, reflecting a 32.20% increase year-on-year due to higher payments across various operational items[12] - Cash inflow from investment activities amounted to ¥1,121,948,444.18, a 92.43% increase, primarily driven by the redemption of financial products[12] - The net cash increase from cash and cash equivalents was ¥965,590,589.44, representing a 48.18% rise, mainly influenced by net cash inflows from investment activities[12] - The company reported a net increase in cash and cash equivalents of 965,590,589.44 CNY, compared to 651,647,055.80 CNY in the previous year[27] - The cash inflow from investment activities totaled 1,121,948,444.18 CNY, up from 583,055,302.79 CNY in the previous year[27] - The cash outflow for investment activities was 716,915,487.09 CNY, compared to 609,324,527.32 CNY in the same quarter last year[27] Research and Development - Research and development expenses surged by 77.77% to ¥39,199,038.29, indicating a significant investment in R&D strategies[11] - Research and development expenses rose to ¥39,199,038.29, up from ¥22,050,936.58, indicating a focus on innovation[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,666[14] - The largest shareholder, China Resources Dong'e Ejiao Co., Ltd., holds 23.50% of the shares, totaling 151,351,731 shares[14] Operational Changes - The company has seen a significant increase in operational expenses, with cash paid for sales and management rising by 36.60% year-on-year[12] - The company engaged in share repurchase activities, resulting in a dramatic increase of 16,087.30% in cash outflows related to financing activities[12] - The company appointed Ren Hui as the new Vice President following the resignation of Lu Jiaxuan[18] Accounting and Reporting - The company did not report any cash inflow from financing activities during the quarter[27] - The company has not yet audited the first quarter report[28] - The company is implementing new accounting standards starting from 2024[28] - The report was released by the board of directors on April 26, 2024[28]

东阿阿胶股份有限公司 对外捐赠管理制度 （2024 年 4 月 24 日 经公司第十届董事会第二十五次审议修订） 第一章 总则 第一条 为推动东阿阿胶股份有限公司（以下简称"公司"）积极 履行社会责任，规范对外捐赠行为，进一步加强捐赠事项管理，根据 《中华人民共和国公益事业捐赠法》《中华人民共和国公司法》、国务 院国资委《关于加强中央企业对外捐赠管理有关事项的通知》等法律 法规及规范性文件，特制定本制度。 第二条 本制度适用于公司及其控股子公司。 第二章 对外捐赠的定义 第五条 权责清晰原则。公司经营者或者其他职工不得将公司拥 有的财产以个人名义对外捐赠，公司对外捐赠有权要求受赠人落实自 己正当的捐赠意愿，不能将捐赠财产挪作他用。 第六条 量力而行原则。公司应在力所能及的范围内，积极参加 社会公益活动，已经发生亏损或者由于对外捐赠将导致亏损或者影响 1 公司正常生产经营的，除特殊情况以外，不得对外捐赠。 第七条 诚实守信原则。公司按照内部议事规范审议决定并已经 向社会公众或者受赠对象承诺的捐赠，必须诚实履行。 第四章 对外捐赠的范围 第八条 公司可以用于对外捐赠的财产包括现金、实物资产（库 存商品和其他物资） ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2024-25 东阿阿胶股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东大会届次：2023年年度股东大会。 5．会议的召开方式：采用现场表决与网络投票相结合的方式 （1）现场表决：股东本人或委托他人出席现场会议； （2）网络投票：公司通过深圳证券交易所交易系统和互联网投票系统向全 体股东提供网络形式的投票平台，股东可以在网络投票时间内，通过上述系统行 使表决权； （3）同一表决权只能选择现场投票、深圳证券交易所交易系统投票、深圳 证券交易所互联网系统投票中的一种。同一表决权出现重复表决的，以第一次投 2．股东大会的召集人：东阿阿胶股份有限公司（以下简称"公司"）第十届 董事会；公司第十届董事会第二十五次会议，审议通过了《关于召开2023年年度 股东大会的议案》。 3．会议召开的合法合规性：本次股东大会会议的召开，符合有关法律、行 政法规、部门规章、规范性文件、深交所业务规则和《公司章程》等规定。 4．会议召开日期和时间 ...

3．会议应出席会议监事 5 人，实际出席会议监事 5 人。 4．本次监事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、监事会会议审议情况 证券代码：000423 证券简称：东阿阿胶 公告编号：2024-21 东阿阿胶股份有限公司 第十届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1．东阿阿胶股份有限公司（以下简称"公司"）第十届监事会第十五次会 议，于 2024 年 4 月 21 日以邮件方式发出会议通知。 2．本次监事会会议，于 2024 年 4 月 24 日以通讯表决方式召开。 表决结果：5 票同意，0 票反对，0 票弃权。 本次会议审议并通过了以下议案： 1.《关于 2024 年第一季度报告的议案》 经审议，监事会认为公司《2024 年第一季度报告》的编制，符合法律法规、 中国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整地反映了 公司实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 公司《2024 年第一季度报告》是按照中国证监会和深圳证券 ...

东阿阿胶股份有限公司 关于在珠海华润银行办理存款及结算业务的关联交易公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 证券代码：000423 证券简称：东阿阿胶 公告编号：2024-23 2021 年 4 月 27 日经董事会批准，东阿阿胶股份有限公司（以下简称"公司"） 在珠海华润银行股份有限公司（以下简称"珠海华润银行"）办理了结算及存款 业务，其中确定日最高存款额度不超过人民币 2 亿元，期限为三年。在前期友好 合作的基础上，本着互惠互利原则，珠海华润银行承诺，在办理结算业务时免除 结算手续费，并且存款利率上浮不低于 10%。基于以上因素，拟继续在珠海华润 银行办理存款及结算业务，存款额度不超过人民币 2 亿元，期限自董事会批准之 日起三年。 公司控股股东华润东阿阿胶有限公司为华润股份有限公司之控股下属公司， 珠海华润银行为华润股份有限公司之子公司，因此本次交易构成关联交易。 公司第十届董事会第二十五次会议，以 6 票同意、0 票反对、0 票弃权，审 议通过了《关于在珠海华润银行办理存款及结算业务的关联交易议案》，关联董 事白晓松先 ...

Investment Rating - The report gives a "Hold" rating for the company with a target price of 75.56 CNY based on a 35 PE for 2024, resulting in a market capitalization of 486.63 billion CNY [4][9]. Core Views - The company is positioned as a leader in the health supplement industry, focusing on a dual-driven model of "pharmaceuticals + health consumer products" [15][17]. - The company aims to clear product inventory to stabilize supply-demand and price relationships, which had been disrupted by previous price hikes and inventory accumulation [2][36]. - The implementation of stock incentives reflects the company's confidence in its growth trajectory, with net profit growth targets set at no less than 20% from 2022 to 2026 [2][9]. Summary by Sections Company Overview - The company, established in 1952, has evolved into a publicly listed entity and is recognized as a standard setter in the health supplement industry, particularly in the production of Ejiao (donkey-hide gelatin) [15][17]. Product Strategy - The company focuses on enhancing the brand power of its core product, Ejiao, while expanding into health consumer products like "Peach Blossom Princess" Ejiao cake and Ejiao powder, targeting younger demographics [2][7]. - The company is also developing a product matrix for men's health supplements, supported by academic research [2][15]. Financial Performance - Revenue is projected to grow from 55.23 billion CNY in 2024 to 76.09 billion CNY in 2026, with a compound annual growth rate (CAGR) of approximately 17% [9][24]. - Net profit is expected to increase from 13.90 billion CNY in 2024 to 19.68 billion CNY in 2026, with growth rates of 21%, 20%, and 18% respectively [9][24]. Market Position - The company has successfully cleared excess inventory, which has helped restore market confidence and stabilize pricing [2][36]. - The company’s products, particularly Ejiao and its derivatives, dominate the market, with Ejiao alone generating over 51 billion CNY in sales [51][55]. Future Outlook - The company is expected to continue leveraging its brand strength and marketing capabilities to drive growth in both traditional and new product lines, including health supplements [9][8]. - The report highlights the potential for the company to expand its market share in the health supplement sector, which is projected to grow significantly in the coming years [55][56].

Investment Rating - The report assigns an investment rating of "Buy" for the company, indicating a strong performance relative to the benchmark [1]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 334-357 million yuan in Q1 2024, representing a year-on-year growth of 45-55%. The non-recurring net profit is projected to be 309-332 million yuan, with a growth of 46-56% [1][2]. - The company maintains a "dual-driven" growth model focusing on both pharmaceutical and health consumer products, aiming to enhance brand recognition and expand its product offerings [1][2]. - The main product line, which includes various Ejiao products, generated revenue of 4.363 billion yuan in 2023, accounting for 92.55% of total revenue, with a gross margin of 72.37% [1][2]. Financial Performance Summary - Total revenue is projected to grow from 4.715 billion yuan in 2023 to 5.650 billion yuan in 2024, reflecting a year-on-year growth rate of 19.8% [2]. - The net profit attributable to shareholders is expected to increase from 1.151 billion yuan in 2023 to 1.447 billion yuan in 2024, with a growth rate of 25.8% [2]. - The gross margin is forecasted to remain stable, increasing slightly from 70.2% in 2023 to 70.4% in 2024 [2]. - The company’s return on equity (ROE) is projected to rise from 10.7% in 2023 to 12.3% in 2024 [2]. Business Strategy - The company plans to enhance its brand positioning as a top-tier health supplement brand while focusing on digital and integrated marketing strategies to build brand barriers [1][2]. - The report emphasizes the importance of innovation and a robust R&D framework to drive business growth and improve operational performance [1][2].